XBI

Thursday's ETF Movers: XBI, SIL

BBH: Buy Rating, As Tech Investors Look Beyond FAANG

VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. The VanEck biotech ETF (BBH) is under-discovered compared to peers, offers potential for trend change in biotech sector.

Biotech ETF (XBI) Rallied from the Blue Box Hitting Target

The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that tracks the biotechnology segment of the S&p Total Market Index. XBI is expected to continue the bullish movement. The next target for XBI comes around 108.85.

Weekly Report: what happened at XBI last week (0715-0719)?

Notable ETF Outflow Detected - XBI, EXAS, SRPT, UTHR

Small-cap stocks are perking up. Here’s how to pick winners. 

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals, Inc. (REGN) is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1. The company is expected to report a profit of $8.89 per share. REGN reported Q1 earnings on May 2. The stock is up 23.6% on a YTD basis.

HQH: Discount Remains Attractive With A Now Higher Distribution Rate

Abrdn Healthcare Investors Fund focuses on the more cyclical biotech space, with over half of its portfolio allocated there. The fund's managed distribution policy was increased significantly since our prior update. The abrdn healthcare investors fund continues to trade at an attractive discount. Discount Narrows With Distribution Increase But Remains Appealing.